Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Safety and PK Study of XW10508 in Healthy Adults
NCT04966832Phase 1Completed
- Sponsor
- XWPharma
- Start
- Jul 2021
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in major depressive disorder (MDD) and chronic pain comparing XW10508 with Placebo (2 arms). Primary endpoint: Incidence, severity, and causality of adverse events (AEs) up to 12 Days. Started Jul 2021; status: completed.
02
Drugs
XW10508
03
Conditions
major depressive disorder (MDD)chronic pain
Beyond the preview
Go deeper on NCT04966832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04966832.